Contemporary role of androgen deprivation therapy for prostate cancer.

ABSTRACT:

Context

Androgen deprivation therapy (ADT) for prostate cancer (PCa) represents one of the most effective systemic palliative treatments known for solid tumors. Although clinical trials have assessed the role of ADT in patients with metastatic and advanced locoregional disease, the risk-benefit ratio, especially in earlier stages, remains poorly defined. Given the mounting evidence for potentially life-threatening adverse effects with short- and long-term ADT, it is important to redefine the role of ADT for this disease.

Objective

Review the published experience with currently available ADT approaches in various contemporary clinical settings of PCa and reported serious treatment-related adverse events. This review addresses the level of evidence associated with the use of A

SUBMITTER: Pagliarulo V 

PROVIDER: S-EPMC3483081 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature